<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC11398981</article-id>
        <article-id pub-id-type="pmcid-ver">PMC11398981.1</article-id>
        <article-id pub-id-type="pmcaid">11398981</article-id>
        <article-id pub-id-type="pmcaiid">11398981</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS2010991</article-id>
        <article-id pub-id-type="pmid">38995739</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-24-0605</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS2010991</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA2010991</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>A Phase II study assessing Long-Term Response to Ibrutinib Monotherapy in recurrent or refractory CNS Lymphoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Grommes</surname>
              <given-names initials="C">Christian</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nandakumar</surname>
              <given-names initials="S">Subhiksha</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schaff</surname>
              <given-names initials="LR">Lauren R.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gavrilovic</surname>
              <given-names initials="I">Igor</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kaley</surname>
              <given-names initials="TJ">Thomas J.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nolan</surname>
              <given-names initials="CP">Craig P.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Stone</surname>
              <given-names initials="J">Jacqueline</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names initials="AA">Alissa A.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="FN1" ref-type="author-notes">$</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tang</surname>
              <given-names initials="SS">Sarah S.</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wolfe</surname>
              <given-names initials="J">Julia</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bozza</surname>
              <given-names initials="A">Alexis</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wongchai</surname>
              <given-names initials="V">Venissala</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hyde</surname>
              <given-names initials="A">Alisson</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Barrett</surname>
              <given-names initials="E">Emma</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lynch</surname>
              <given-names initials="EA">Elizabeth A.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Madzsar</surname>
              <given-names initials="JT">Juli T.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lin</surname>
              <given-names initials="A">Andrew</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Piotrowski</surname>
              <given-names initials="AF">Anna F.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pentsova</surname>
              <given-names initials="E">Elena</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Francis</surname>
              <given-names initials="JH">Jasmine H.</given-names>
            </name>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hatzoglou</surname>
              <given-names initials="V">Vaios</given-names>
            </name>
            <xref rid="A6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="A4" ref-type="aff">4</xref>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reiner</surname>
              <given-names initials="AS">Anne S.</given-names>
            </name>
            <xref rid="A8" ref-type="aff">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Panageas</surname>
              <given-names initials="KS">Katherine S.</given-names>
            </name>
            <xref rid="A8" ref-type="aff">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>DeAngelis</surname>
              <given-names initials="LM">Lisa M.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mellinghoff</surname>
              <given-names initials="IK">Ingo K.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Departments of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A2"><label>2</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A3"><label>3</label>Department of Neurology, Weill Cornell Medical College, New York, NY 10021, USA.</aff>
        <aff id="A4"><label>4</label>Computational Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A5"><label>5</label>Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A6"><label>6</label>Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A7"><label>7</label>Deprtment of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <aff id="A8"><label>8</label>Epidemiology &amp; Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065, USA.</aff>
        <author-notes>
          <fn fn-type="current-aff" id="FN1">
            <label>$</label>
            <p id="P1">Current affiliations: Department of Neurology, University of Vermont, Burlington, Vermont.</p>
          </fn>
          <fn fn-type="con" id="FN2">
            <p id="P2">AUTORSHIP CONTRIBUTIONS</p>
            <p id="P3"><bold>Conception and design:</bold> C. Grommes, I.K. Mellinghoff</p>
            <p id="P4"><bold>Development of methodology:</bold> C. Grommes, I.K. Mellinghoff, A. A. Thomas</p>
            <p id="P5"><bold>Acquisition of data:</bold> C. Grommes, S.S. Tang, I. Gavrilovic, T.J. Kaley, C.P. Nolan, J. Stone, E. Pentsova, A. F. Piotrowski, A. Lin, J. Wolfe, V. Hatzoglou, L.M. DeAngelis, I.K. Mellinghoff, A. Bozza, A. Hyde<sup>,</sup> E. Barrett, E. A. Lynch, J. T. Madzsar, L. R. Schaff, J. H. Francis</p>
            <p id="P6">Analysis and interpretation of data (e.g., statistical analysis, biostatistics,</p>
            <p id="P7"><bold>computational analysis):</bold> C. Grommes, S. Nandakumar, A.S. Reiner, K.S. Panageas, N. Schultz, I.K. Mellinghoff</p>
            <p id="P8"><bold>Writing, review, and/or revision of the manuscript:</bold> C. Grommes, L. R. Schaff, T.J. Kaley, E. Pentsova, A. Piotrowski, J. Stone, A. Lin, C.P. Nolan, A.S. Reiner, L.M. DeAngelis, I.K. Mellinghoff</p>
            <p id="P9"><bold>Administrative, technical, or material support:</bold> C. Grommes, E. Barrett, E. A. Lynch, J. T. Madzsar, A. Hyde, J. Wolfe, I.K. Mellinghoff</p>
            <p id="P10"><bold>Study supervision:</bold> C. Grommes, L. R. Schaff, I.K. Mellinghoff</p>
          </fn>
          <corresp id="CR1"><bold>Corresponding Author:</bold> Christian Grommes; 1275 York Avenue; New York, NY 10065; <email>grommesc@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN3">
            <p id="P58">Conflict-of-Interest Statement</p>
            <p id="P59">CG has acted as consultant for BTG, Roche, ONO, and Curis, has received speakers’ bureau honoraria from Ono and Hartford HealthCare and received research funding (institution) from Pharmacyclics, Bayer, Bristol Myer Squib. LRS has acted as consultant for BTG and Guidepoint and received research funding from BTG and Merck &amp; Co. ALL has received research funding from Bristol Myer Squib. LMD has acted as consultant for Sapience Therapeutics. IKM has acted as consultation for Agios, Black Diamond Therapeutics, Erasca, Roche, Novartis, Prelude, Servier Pharmaceuticals, and Voyager Therapeutics and received honoraria from Roche, Prelude Therapeutics, Black Diamond Therapeutics, and Hartford HealthCare. All other authors have no relevant conflict of interests.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>13</day>
          <month>9</month>
          <year>2024</year>
        </pub-date>
        <volume>30</volume>
        <issue>18</issue>
        <issue-id pub-id-type="pmc-issue-id">470744</issue-id>
        <fpage>4005</fpage>
        <lpage>4015</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>01</day>
              <month>08</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>13</day>
              <month>03</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>13</day>
              <month>03</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-03-13 00:25:36.683">
              <day>13</day>
              <month>03</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2010991.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Background:</title>
            <p id="P11">Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK). We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary (PCNSL) or secondary CNS lymphoma (SCNSL).</p>
          </sec>
          <sec id="S2">
            <title>Patients and Methods:</title>
            <p id="P12">We enrolled 26 additional patients with r/r PCNSL/SCNSL into the dose-expansion cohort of the trial into a combined cohort of 46 patients (31 PCNSLs, 15 SCNSLs). Patients received ibrutinib at 560mg or 840mg daily in the dose-escalation and 840mg daily in the expansion cohort. Median follow up was 49.9 and 62.1 months for patients with PCNSL and SCNSL, respectively. We sequenced DNA from available tumor biopsies and cerebrospinal fluid (CSF) collected before and during ibrutinib therapy.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P13">Tumor responses were observed in 23/31 (74%) PCNSLs and 9/15 (60%) SCNSLs, including 12 complete responses in PCNSL and 7 in SCNSL. Median progression-free survival (PFS) for PCNSL was 4.5 months (95%CI: 2.8–9.2) with 1y-PFS at 23.7% (95%CI: 12.4%–45.1%). Median duration of response (DOR) in the 23 PCNSL responders was 5.5 months. Median PFS in SCNSL was 5.3 months (95%CI: 1.3–14.5) with a median DOR 8.7 months for the 9 responders. Exploratory biomarker analysis suggests that mutations in TBL1XR1 may be associated with a long-term response to ibrutinib in PCNSL (p=0.0075). Clearance of circulating tumor DNA from CSF was associated with complete and long-term ibrutinib response.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P14">Our study confirms single-agent activity of ibrutinib in r/r CNS lymphoma and identifies molecular determinants of response based on long-term follow up.</p>
          </sec>
          <sec id="S5">
            <title>Clinical Trial Information:</title>
            <p id="P15">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02315326" ext-link-type="uri">NCT02315326</ext-link>
</p>
          </sec>
        </abstract>
        <abstract abstract-type="summary" id="ABS2">
          <title>STATEMENT OF TRANSLATIONAL RELEVANCE:</title>
          <p id="P16">This investigator-initiated trial shows that ibrutinib monotherapy can result in long term responses in heavily pretreated recurrent/refractory CNS lymphoma, leading to a 10.1% progression free survival at 3 years for primary and 20.7% for secondary CNS lymphoma. This is the largest patient population treated with daily dosed ibrutinib at 840 mg. Moreover, exploratory biomarker analysis suggest that TBL1XR1 mutations are associated with longer treatment response to single agent ibrutinib. We assess the role of on-treatment cerebrospinal fluid liquid biopsy using the MSK-IMPACT sequencing panel and demonstrate that clearance of CSF ctDNA is associated with better clinical outcome.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
